nach oben

International Ophthalmology

Erschienen in:

01.12.2024 | Original Paper

The effect of adjuvant Mitomycin C during vitrectomy on functional and anatomical outcomes in patients with severe diabetic tractional retinal detachment

verfasst von: Ihsan Gokhan Gurelik, Huseyin Baran Ozdemir, Burak Acar

Erschienen in: International Ophthalmology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the effect of adjuvant Mitomycin C (MMC) use on the anatomical and functional success of vitreoretinal surgery (VRS) in severe diabetic tractional retinal detachment (dTRD) patients.

Methods

A retrospective analysis of consecutive patients undergoing VRS due to severe dTRD was conducted. Patients were categorized into those who received 20 µg/0.1 mL MMC via MMC sandwich method (Group 1) and those who did not (Group 2). Demographics, surgical characteristics, visual outcomes, and complications that may related to MMC were analyzed.

Results

A total of 25 eyes were included, 13 in Group 1 and 12 in Group 2. No statistical difference was observed in baseline characteristics between the groups. The mean best-corrected visual acuity was 1.90 ± 0.43 logMAR and 1.93 ± 0.41 logMAR preoperatively and 1.60 ± 0.78 logMAR and 1.56 ± 0.78 logMAR postoperatively in Groups 1 and 2, respectively (p = 0.154). The postoperative mean intraocular pressure was 16.23 ± 2.55 mmHg and 13.08 ± 4.94 mmHg in Groups 1 and 2, respectively (p = 0.225). The rate of re-surgery was significantly lower in Group 1 (0% vs. 41.7% in Group 2, p = 0.015). Retina was attached in all patients at the last visit. No MMC-related complication was recorded.

Conclusion

Intraoperative adjuvant MMC application for severe dTRD significantly reduces re-surgery rates with good anatomical and functional outcomes safely.

The Diabetic Retinopathy Vitrectomy Study Research Group (1988) Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision; clinical application of results of a randomized trial:diabetic retinopathy vitrectomy study report 4. Ophthalmology 95(10):1321–1334. https://doi.org/10.1016/s0161-6420(88)33014-9CrossRef

La Heij EC, Tecim S, Kessels AG, Liem AT, Japing WJ, Hendrikse F (2004) Clinical variables and their relation to visual outcome after vitrectomy in eyes with diabetic retinal traction detachment. Graefes Arch Clin Exp Ophthalmol 242:210–217CrossRefPubMed

Meleth AD, Carvounis PE (2014) Outcomes of vitrectomy for tractional retinal detachment in diabetic retinopathy. Int Ophthalmol Clin 54(2):127–139CrossRefPubMed

McCullough P, Mohite A, Virgili G, Lois N (2023) Outcomes and complications of pars plana vitrectomy for tractional retinal detachment in people with diabetes: a systematic review and meta-analysis. JAMA Ophthalmol 141(2):186–195. https://doi.org/10.1001/jamaophthalmol.2022.5817CrossRefPubMedPubMedCentral

Al-Khersan H, Venincasa MJ, Kloosterboer A, Sridhar J, Smiddy WE, Townsend JH et al (2020) Pars plana vitrectomy reoperations for complications of proliferative diabetic retinopathy. Clin Ophthalmol (Auckland, NZ) 14:1559–1563. https://doi.org/10.2147/opth.s252285CrossRef

Gupta B, Wong R, Sivaprasad S, Williamson TH (2012) Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice. Eye (London, England) 26(4):576–582. https://doi.org/10.1038/eye.2011.348CrossRefPubMed

Farouk MM, Naito T, Sayed KM, Nagasawa T, Katome T, Radwan G et al (2011) Outcomes of 25-gauge vitrectomy for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 249(3):369–376. https://doi.org/10.1007/s00417-010-1506-7CrossRefPubMed

Le Mer Y, Korobelnik JF, Morel C, Ullern M, Berrod JP (1999) TPA-assisted vitrectomy for proliferative diabetic retinopathy: results of a double-masked, multicenter trial. Retina (Philadelphia, Pa) 19(5):378–382. https://doi.org/10.1097/00006982-199909000-00002CrossRefPubMed

Ghasemi Falavarjani K, Modarres M, Hadavandkhani A, Karimi MA (2015) Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy. Eye 29(9):1199–1203. https://doi.org/10.1038/eye.2015.114CrossRefPubMedPubMedCentral

10.

Iglicki M, Zur D, Fung A, Gabrielle P-H, Lupidi M, Santos R et al (2019) Tractional diabetic retinal detachment surgery with co-adjuvant intravitreal dexamethasone implant: the tradition study. Acta Diabetol 56:1141–1147CrossRefPubMed

11.

Pratt WB (1994) The anticancer drugs. Oxford University Press, USA

12.

Crowston JG, Akbar AN, Constable PH, Occleston NL, Daniels JT, Khaw PT (1998) Antimetabolite-induced apoptosis in Tenon’s capsule fibroblasts. Investig Ophthalmol Vis Sci 39(2):449–454

13.

Khaw PT, Doyle JW, Sherwood MB, Grierson I, Schultz G, McGorray S (1993) Prolonged localized tissue effects from 5-minute exposures to fluorouracil and Mitomycin C. Arch Ophthalmol 111(2):263–267. https://doi.org/10.1001/archopht.1993.01090020117035CrossRefPubMed

14.

Assi A, Khoueir Z, Helou C, Fakhoury H, Cherfan G (2019) Intraocular application of Mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe intraocular foreign body injuries. Eye 33(8):1261–1270CrossRefPubMedPubMedCentral

15.

Gürelik G, Sül S, Üçgül AY (2021) Intraocular Mitomycin C use in the treatment and prophylaxis of proliferative vitreoretinopathy in severe traumatic retinal detachments. Eur J Ophthalmol 31(6):3284–3293CrossRefPubMed

16.

Gurelik G, Korkmaz S, Uyar Gocun P, Sul S (2022) Evaluation the safety of a new intraocular Mitomycin C application technique in the rabbit. Ret-Vit 31(4):387–393. https://doi.org/10.37845/ret.vit.2022.31.66CrossRef

17.

Garner A (1993) Histopathology of diabetic retinopathy in man. Eye 7(2):250–253CrossRefPubMed

18.

Pastor JC, Rojas J, Pastor-Idoate S, Di Lauro S, Gonzalez-Buendia L, Delgado-Tirado S (2016) Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res 51:125–155CrossRefPubMed

19.

Mirshahi A, Lashay A, Mehrabi Bahar MR, Abrishami M (2018) Consequences of inadvertent intravitreal Mitomycin C injection. Int J Ret Vit 4(1):7. https://doi.org/10.1186/s40942-018-0110-6CrossRef

20.

Gui F, You Z, Fu S, Wu H, Zhang Y (2020) endothelial dysfunction in diabetic retinopathy. Front Endocrinol 11:591. https://doi.org/10.3389/fendo.2020.00591CrossRef

21.

Iyer SSR, Lagrew MK, Tillit SM, Roohipourmoallai R, Korntner S (2021) The vitreous ecosystem in diabetic retinopathy: insight into the patho-mechanisms of disease. Int J Mol Sci 22(13):7142CrossRefPubMedPubMedCentral

22.

Tamaki K, Usui-Ouchi A, Murakami A, Ebihara N (2016) Fibrocytes and fibrovascular membrane formation in proliferative diabetic retinopathy. Investig Ophthalmol Vis Sci 57(11):4999–5005. https://doi.org/10.1167/iovs.16-19798CrossRef

23.

Roy S, Amin S, Roy S (2016) Retinal fibrosis in diabetic retinopathy. Exp Eye Res 142:71–75. https://doi.org/10.1016/j.exer.2015.04.004CrossRefPubMedPubMedCentral

24.

Zhou J, Wang S, Xia X (2012) Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res 37(5):416–420CrossRefPubMed

25.

Abdelhadi AM, Helaly HA, Abuelkeir A (2020) Evaluation of retinal detachment after diabetic vitrectomy: causes and ways of management. Clin Ophthalmol (Auckland, NZ) 14:53–60. https://doi.org/10.2147/opth.s235757CrossRef

26.

Stewart MW, Browning DJ, Landers MB (2018) Current management of diabetic tractional retinal detachments. Indian J Ophthalmol 66(12):1751–1762. https://doi.org/10.4103/ijo.IJO_1217_18CrossRefPubMedPubMedCentral

27.

Yau GL, Silva PS, Arrigg PG, Sun JK (2018) Postoperative complications of pars plana vitrectomy for diabetic retinal disease. Semin Ophthalmol 33(1):126–133. https://doi.org/10.1080/08820538.2017.1353832CrossRefPubMed

28.

Jonas J, Söfker A, Degenring R (2003) Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 13(5):468–473CrossRefPubMed

29.

Chan ES, Cronstein BN (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res Ther 4(4):1–8

30.

Taylor SR, Habot-Wilner Z, Pacheco P, Lightman S (2012) Intravitreal methotrexate in uveitis. Ophthalmol 119(4):878–879. https://doi.org/10.1016/j.ophtha.2011.12.015CrossRef

Titel: The effect of adjuvant Mitomycin C during vitrectomy on functional and anatomical outcomes in patients with severe diabetic tractional retinal detachment
verfasst von: Ihsan Gokhan Gurelik
Huseyin Baran Ozdemir
Burak Acar
Publikationsdatum: 01.12.2024
Verlag: Springer Netherlands
Erschienen in: International Ophthalmology / Ausgabe 1/2024
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-024-03152-3

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

The effect of adjuvant Mitomycin C during vitrectomy on functional and anatomical outcomes in patients with severe diabetic tractional retinal detachment

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

The effect of combination therapy with intravitreal bevacizumab and topical timolol–dorzolamide eye drops on diabetic macular edema: a double-blind randomized controlled trial

Selective laser trabeculoplasty in the treatment of juvenile open angle glaucoma patients under 25 years of age

Zone 1 trauma: wound dehiscence compared to primary trauma

Plastic vs. glass: the effect of the synthetic material in contact with DMEK tissue during staining on endothelial cell loss

LASIK is associated with early cataract surgery in healthy patients

The role of endothelial growth factor and tear levels in diabetic retinopathy in type 2 diabetes

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde